A circulating microRNA-based diagnostic model for breast cancer, in which the miR-139-3p/RPA2 axis regulates the sensitivity to DNA-damaging agents

Key Points

• The diagnostic model identifies key microRNAs that may affect breast cancer treatment outcomes, particularly regarding DNA damage sensitivity.
• The investigation highlighted the significant role of the miR-139-3p/RPA2 axis in regulating responses to DNA-damaging drugs.
• Assessment utilizing liquid biopsy techniques allows for less invasive diagnosis and monitoring of breast cancer.
• Targeting microRNA pathways may enable new therapeutic strategies, yet further validation is needed for clinical application.

Abstract